Zobrazeno 1 - 3
of 3
pro vyhledávání: '"C M Abitbol"'
Publikováno v:
Journal of Crohn's and Colitis. 16:i429-i430
Background Extraintestinal manifestations (EIM) occur in up to 50 % of patients with inflammatory bowel disease (IBD) and are associated with significant morbidity and diminished quality of life. Ustekinumab (UST) and vedolizumab (VDZ) are effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aed91a73ab72e656d10aa7e9f3b2d033
https://doi.org/10.1093/ecco-jcc/jjab232.577
https://doi.org/10.1093/ecco-jcc/jjab232.577
Autor:
A Levartovsky, I Cohen, C M Abitbol, M Yavzori, E Fudim, O Picard, U Kopylov, S Ben-Horin, B Ungar
Publikováno v:
Journal of Crohn's and Colitis. 16:i451-i451
Background Vedolizumab trough serum levels have been associated with clinical and endoscopic response in patients with inflammatory bowel disease (IBD), albeit findings have not been conclusive. A recent study demonstrated that higher trough vedolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b95695f44feaa1ef8be051319729e2a0
https://doi.org/10.1093/ecco-jcc/jjab232.611
https://doi.org/10.1093/ecco-jcc/jjab232.611
Publikováno v:
Journal of Crohn's and Colitis. 16:i382-i382
Background Acute severe ulcerative colitis (ASUC) is considered a medical emergency and is associated with high rates of colectomy and even death. Intra-venous corticosteroids serve as first line therapy for ASUC. Patients who fail to respond will pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77d69ebc4fca54ff39b77c5c8a0bf774
https://doi.org/10.1093/ecco-jcc/jjab232.508
https://doi.org/10.1093/ecco-jcc/jjab232.508